Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Breast Neoplasms | 25 | 2022 | 1129 | 2.820 |
Why?
|
Intercellular Signaling Peptides and Proteins | 8 | 2024 | 158 | 2.390 |
Why?
|
Membrane Proteins | 9 | 2024 | 843 | 1.810 |
Why?
|
Plant Extracts | 5 | 2018 | 160 | 1.770 |
Why?
|
Mammary Glands, Animal | 11 | 2022 | 79 | 1.670 |
Why?
|
Estrogens | 6 | 2020 | 113 | 1.610 |
Why?
|
Food Hypersensitivity | 8 | 2025 | 17 | 1.520 |
Why?
|
Breast | 5 | 2024 | 173 | 1.490 |
Why?
|
Rhodiola | 5 | 2018 | 15 | 1.480 |
Why?
|
Mast Cells | 8 | 2025 | 41 | 1.430 |
Why?
|
Epithelial Cells | 8 | 2022 | 375 | 1.370 |
Why?
|
Gene Expression Regulation, Neoplastic | 7 | 2020 | 484 | 1.210 |
Why?
|
Macrophages | 4 | 2024 | 1006 | 1.110 |
Why?
|
Mammary Glands, Human | 5 | 2019 | 50 | 1.000 |
Why?
|
Intracellular Signaling Peptides and Proteins | 3 | 2024 | 324 | 0.990 |
Why?
|
Phytotherapy | 3 | 2018 | 52 | 0.920 |
Why?
|
Insulin-Like Growth Factor I | 2 | 2017 | 84 | 0.850 |
Why?
|
Biomarkers, Tumor | 6 | 2020 | 454 | 0.840 |
Why?
|
Wnt Signaling Pathway | 4 | 2024 | 71 | 0.840 |
Why?
|
DNA Methylation | 4 | 2020 | 275 | 0.840 |
Why?
|
Cell Proliferation | 11 | 2020 | 944 | 0.830 |
Why?
|
Receptors, Aryl Hydrocarbon | 1 | 2022 | 16 | 0.810 |
Why?
|
Mammary Neoplasms, Animal | 3 | 2022 | 30 | 0.800 |
Why?
|
Polychlorinated Biphenyls | 1 | 2022 | 39 | 0.790 |
Why?
|
Mice | 29 | 2025 | 10259 | 0.770 |
Why?
|
Milk, Human | 4 | 2022 | 94 | 0.740 |
Why?
|
Tumor Suppressor Protein p53 | 6 | 2021 | 299 | 0.710 |
Why?
|
Immunoglobulin E | 6 | 2025 | 85 | 0.690 |
Why?
|
Macrophage Activation | 1 | 2020 | 119 | 0.690 |
Why?
|
Female | 41 | 2024 | 30829 | 0.680 |
Why?
|
Proteins | 2 | 2017 | 742 | 0.670 |
Why?
|
Environmental Exposure | 2 | 2020 | 204 | 0.660 |
Why?
|
Animals | 33 | 2025 | 19616 | 0.640 |
Why?
|
Receptors, Estrogen | 5 | 2020 | 124 | 0.630 |
Why?
|
Tumor Necrosis Factor-alpha | 3 | 2024 | 580 | 0.630 |
Why?
|
Interleukin-10 | 4 | 2025 | 147 | 0.620 |
Why?
|
Antineoplastic Agents | 5 | 2018 | 643 | 0.610 |
Why?
|
Mice, Knockout | 9 | 2025 | 1988 | 0.580 |
Why?
|
Early Growth Response Protein 2 | 1 | 2017 | 8 | 0.580 |
Why?
|
Disease Models, Animal | 10 | 2025 | 2062 | 0.570 |
Why?
|
Cell Line, Tumor | 10 | 2020 | 1370 | 0.560 |
Why?
|
Mice, Inbred BALB C | 11 | 2024 | 880 | 0.550 |
Why?
|
Interleukin-1 Receptor-Like 1 Protein | 3 | 2025 | 7 | 0.540 |
Why?
|
Transforming Growth Factor beta | 3 | 2017 | 162 | 0.540 |
Why?
|
Obesity | 5 | 2020 | 1189 | 0.530 |
Why?
|
Mammaplasty | 2 | 2014 | 44 | 0.520 |
Why?
|
Signal Transduction | 8 | 2025 | 2890 | 0.510 |
Why?
|
Transcriptome | 6 | 2020 | 324 | 0.500 |
Why?
|
Melanoma, Experimental | 1 | 2015 | 42 | 0.490 |
Why?
|
Humans | 42 | 2024 | 59329 | 0.480 |
Why?
|
Energy Metabolism | 1 | 2017 | 348 | 0.470 |
Why?
|
Neoplasms, Glandular and Epithelial | 1 | 2014 | 13 | 0.460 |
Why?
|
Leukocytes | 1 | 2014 | 108 | 0.450 |
Why?
|
Inflammation | 4 | 2024 | 1101 | 0.440 |
Why?
|
Phenols | 2 | 2018 | 74 | 0.440 |
Why?
|
Glioblastoma | 1 | 2015 | 156 | 0.430 |
Why?
|
Adiposity | 1 | 2013 | 81 | 0.430 |
Why?
|
Progesterone | 3 | 2008 | 157 | 0.420 |
Why?
|
Apoptosis | 4 | 2020 | 1038 | 0.410 |
Why?
|
Mass Spectrometry | 1 | 2014 | 285 | 0.400 |
Why?
|
Endocrine Disruptors | 3 | 2022 | 74 | 0.390 |
Why?
|
Brain Neoplasms | 1 | 2015 | 306 | 0.390 |
Why?
|
Parabens | 2 | 2021 | 4 | 0.360 |
Why?
|
Glucose | 1 | 2013 | 444 | 0.360 |
Why?
|
Benzophenones | 2 | 2020 | 17 | 0.350 |
Why?
|
Prodrugs | 3 | 2016 | 32 | 0.340 |
Why?
|
Doxorubicin | 3 | 2016 | 99 | 0.340 |
Why?
|
Cells, Cultured | 7 | 2021 | 2103 | 0.330 |
Why?
|
Phosphorylcholine | 3 | 2016 | 41 | 0.320 |
Why?
|
Cytokines | 5 | 2022 | 906 | 0.320 |
Why?
|
Triple Negative Breast Neoplasms | 3 | 2021 | 59 | 0.310 |
Why?
|
Interleukin-33 | 2 | 2025 | 18 | 0.300 |
Why?
|
Pregnancy | 6 | 2024 | 2352 | 0.300 |
Why?
|
Tissue Culture Techniques | 2 | 2020 | 31 | 0.300 |
Why?
|
Cell Respiration | 2 | 2018 | 21 | 0.300 |
Why?
|
Cell Death | 1 | 2008 | 267 | 0.280 |
Why?
|
beta Catenin | 3 | 2017 | 85 | 0.270 |
Why?
|
Gene Expression Regulation | 5 | 2021 | 1539 | 0.260 |
Why?
|
Immunohistochemistry | 4 | 2015 | 846 | 0.260 |
Why?
|
Plant Roots | 2 | 2016 | 61 | 0.250 |
Why?
|
Transcriptional Activation | 2 | 2016 | 188 | 0.240 |
Why?
|
Spheroids, Cellular | 2 | 2016 | 26 | 0.230 |
Why?
|
Lactation | 2 | 2022 | 70 | 0.230 |
Why?
|
Receptors, Progesterone | 2 | 2015 | 109 | 0.230 |
Why?
|
Interleukin-4 | 1 | 2024 | 137 | 0.230 |
Why?
|
bcl-2-Associated X Protein | 2 | 2014 | 42 | 0.230 |
Why?
|
Intestines | 3 | 2020 | 157 | 0.230 |
Why?
|
Antibodies, Neutralizing | 2 | 2024 | 192 | 0.220 |
Why?
|
Mammary Neoplasms, Experimental | 2 | 2022 | 62 | 0.220 |
Why?
|
Apoptosis Regulatory Proteins | 2 | 2014 | 149 | 0.210 |
Why?
|
Diet, High-Fat | 2 | 2014 | 159 | 0.210 |
Why?
|
Proto-Oncogene Proteins c-myc | 2 | 2014 | 99 | 0.210 |
Why?
|
Cytochrome P-450 CYP1A1 | 1 | 2022 | 12 | 0.200 |
Why?
|
Estrogen Receptor alpha | 3 | 2020 | 47 | 0.200 |
Why?
|
Zeranol | 1 | 2022 | 1 | 0.200 |
Why?
|
Adult | 12 | 2022 | 15735 | 0.200 |
Why?
|
CpG Islands | 2 | 2020 | 212 | 0.200 |
Why?
|
Breast Feeding | 2 | 2022 | 138 | 0.190 |
Why?
|
Gene Expression | 2 | 2022 | 808 | 0.190 |
Why?
|
Polymers | 2 | 2016 | 315 | 0.190 |
Why?
|
Genes, Modifier | 1 | 2021 | 3 | 0.190 |
Why?
|
Li-Fraumeni Syndrome | 1 | 2021 | 7 | 0.190 |
Why?
|
Genes, Neoplasm | 1 | 2021 | 24 | 0.190 |
Why?
|
Middle Aged | 11 | 2022 | 16238 | 0.190 |
Why?
|
Down-Regulation | 2 | 2013 | 306 | 0.190 |
Why?
|
Young Adult | 5 | 2020 | 4321 | 0.190 |
Why?
|
Anti-Allergic Agents | 1 | 2020 | 2 | 0.190 |
Why?
|
Phenotype | 2 | 2017 | 1157 | 0.180 |
Why?
|
MCF-7 Cells | 3 | 2016 | 65 | 0.180 |
Why?
|
Protein Disulfide-Isomerases | 1 | 2020 | 15 | 0.180 |
Why?
|
DNA Breaks, Double-Stranded | 1 | 2021 | 77 | 0.180 |
Why?
|
Tumor Cells, Cultured | 2 | 2020 | 454 | 0.170 |
Why?
|
Cell Polarity | 1 | 2020 | 110 | 0.170 |
Why?
|
Epigenesis, Genetic | 2 | 2020 | 351 | 0.170 |
Why?
|
Ovalbumin | 4 | 2025 | 114 | 0.170 |
Why?
|
DNA Repair | 1 | 2021 | 230 | 0.170 |
Why?
|
Prenatal Exposure Delayed Effects | 1 | 2021 | 164 | 0.170 |
Why?
|
Gene Expression Profiling | 5 | 2019 | 697 | 0.160 |
Why?
|
DNA Replication | 1 | 2021 | 229 | 0.160 |
Why?
|
Enzyme Inhibitors | 1 | 2020 | 338 | 0.160 |
Why?
|
Environmental Pollutants | 1 | 2020 | 90 | 0.160 |
Why?
|
Curcumin | 2 | 2020 | 73 | 0.160 |
Why?
|
Mitochondria | 2 | 2012 | 334 | 0.160 |
Why?
|
Benzhydryl Compounds | 1 | 2018 | 48 | 0.150 |
Why?
|
Quantitative Trait Loci | 1 | 2018 | 72 | 0.150 |
Why?
|
Prognosis | 3 | 2020 | 1564 | 0.140 |
Why?
|
Cell Degranulation | 3 | 2024 | 20 | 0.140 |
Why?
|
Pyruvic Acid | 1 | 2017 | 13 | 0.140 |
Why?
|
Neuroblastoma | 1 | 2018 | 85 | 0.140 |
Why?
|
Axin Protein | 2 | 2017 | 10 | 0.140 |
Why?
|
Metabolomics | 1 | 2017 | 50 | 0.140 |
Why?
|
Neoplasm Recurrence, Local | 1 | 2018 | 301 | 0.140 |
Why?
|
Oxidation-Reduction | 1 | 2017 | 304 | 0.130 |
Why?
|
Adolescent | 5 | 2021 | 5918 | 0.130 |
Why?
|
Mice, 129 Strain | 1 | 2016 | 40 | 0.130 |
Why?
|
Mice, Inbred C57BL | 3 | 2025 | 3190 | 0.130 |
Why?
|
MAP Kinase Signaling System | 1 | 2017 | 201 | 0.130 |
Why?
|
Phosphorylation | 3 | 2015 | 861 | 0.130 |
Why?
|
Mastocytosis | 1 | 2015 | 2 | 0.130 |
Why?
|
Neoplasm Invasiveness | 3 | 2014 | 242 | 0.130 |
Why?
|
Blotting, Western | 2 | 2015 | 595 | 0.130 |
Why?
|
Histones | 1 | 2018 | 463 | 0.120 |
Why?
|
Transforming Growth Factor beta2 | 1 | 2015 | 7 | 0.120 |
Why?
|
Aged | 7 | 2021 | 13295 | 0.120 |
Why?
|
Anaphylaxis | 1 | 2015 | 40 | 0.120 |
Why?
|
Ovarian Neoplasms | 1 | 2016 | 133 | 0.120 |
Why?
|
Mutation | 2 | 2021 | 2427 | 0.120 |
Why?
|
S-Phase Kinase-Associated Proteins | 1 | 2014 | 7 | 0.120 |
Why?
|
Oxidative Phosphorylation | 2 | 2012 | 34 | 0.120 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p27 | 1 | 2014 | 29 | 0.120 |
Why?
|
Real-Time Polymerase Chain Reaction | 1 | 2015 | 192 | 0.120 |
Why?
|
RANK Ligand | 1 | 2014 | 24 | 0.120 |
Why?
|
Epithelial-Mesenchymal Transition | 2 | 2013 | 60 | 0.120 |
Why?
|
Long Interspersed Nucleotide Elements | 1 | 2014 | 17 | 0.120 |
Why?
|
DNA, Neoplasm | 1 | 2014 | 51 | 0.120 |
Why?
|
Parity | 1 | 2014 | 71 | 0.110 |
Why?
|
Genes, Tumor Suppressor | 1 | 2014 | 73 | 0.110 |
Why?
|
Glucose Transport Proteins, Facilitative | 1 | 2013 | 9 | 0.110 |
Why?
|
Gene Deletion | 1 | 2015 | 298 | 0.110 |
Why?
|
Bcl-2-Like Protein 11 | 1 | 2013 | 18 | 0.110 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2013 | 52 | 0.110 |
Why?
|
Biopsy | 1 | 2015 | 373 | 0.110 |
Why?
|
Ovary | 1 | 2013 | 96 | 0.110 |
Why?
|
rhoA GTP-Binding Protein | 1 | 2013 | 27 | 0.110 |
Why?
|
Matrix Metalloproteinase 2 | 1 | 2013 | 28 | 0.110 |
Why?
|
Adipose Tissue, White | 1 | 2013 | 82 | 0.110 |
Why?
|
Gene Expression Regulation, Enzymologic | 1 | 2013 | 131 | 0.110 |
Why?
|
Cell Line | 2 | 2015 | 2014 | 0.110 |
Why?
|
Dietary Fats | 1 | 2014 | 204 | 0.110 |
Why?
|
Caspase 3 | 1 | 2013 | 105 | 0.110 |
Why?
|
Lipogenesis | 1 | 2013 | 65 | 0.110 |
Why?
|
Matrix Metalloproteinase 9 | 1 | 2013 | 59 | 0.110 |
Why?
|
Infant | 3 | 2022 | 1527 | 0.100 |
Why?
|
Tumor Suppressor Proteins | 1 | 2014 | 193 | 0.100 |
Why?
|
Estradiol | 2 | 2018 | 242 | 0.100 |
Why?
|
Polymerase Chain Reaction | 1 | 2014 | 500 | 0.100 |
Why?
|
Fatty Liver | 1 | 2013 | 97 | 0.100 |
Why?
|
Fluorobenzenes | 1 | 2012 | 5 | 0.100 |
Why?
|
Fluorocarbon Polymers | 1 | 2012 | 3 | 0.100 |
Why?
|
Xenograft Model Antitumor Assays | 2 | 2014 | 180 | 0.100 |
Why?
|
Zebrafish Proteins | 1 | 2013 | 150 | 0.100 |
Why?
|
Methacrylates | 1 | 2012 | 37 | 0.100 |
Why?
|
Muramidase | 1 | 2012 | 47 | 0.100 |
Why?
|
Wnt Proteins | 1 | 2012 | 91 | 0.100 |
Why?
|
Morphogenesis | 1 | 2012 | 112 | 0.100 |
Why?
|
Body Weight | 1 | 2013 | 378 | 0.100 |
Why?
|
Proto-Oncogene Proteins | 1 | 2013 | 315 | 0.100 |
Why?
|
DNA Damage | 1 | 2013 | 277 | 0.100 |
Why?
|
Immunoglobulin A | 2 | 2022 | 93 | 0.100 |
Why?
|
Electron Transport Complex I | 1 | 2011 | 16 | 0.090 |
Why?
|
Zinc Finger E-box Binding Homeobox 2 | 1 | 2011 | 1 | 0.090 |
Why?
|
Homeostasis | 1 | 2013 | 340 | 0.090 |
Why?
|
Organ Culture Techniques | 2 | 2008 | 70 | 0.090 |
Why?
|
Mitogen-Activated Protein Kinase 3 | 1 | 2011 | 40 | 0.090 |
Why?
|
Telomerase | 1 | 2011 | 30 | 0.090 |
Why?
|
Mitogen-Activated Protein Kinase 1 | 1 | 2011 | 44 | 0.090 |
Why?
|
Disease Progression | 2 | 2019 | 1040 | 0.090 |
Why?
|
Pyrroles | 1 | 2011 | 49 | 0.090 |
Why?
|
Cell Movement | 2 | 2013 | 422 | 0.090 |
Why?
|
Th2 Cells | 2 | 2024 | 98 | 0.090 |
Why?
|
MicroRNAs | 1 | 2016 | 619 | 0.090 |
Why?
|
Oxygen Consumption | 1 | 2011 | 199 | 0.090 |
Why?
|
Gene Knockdown Techniques | 1 | 2011 | 193 | 0.090 |
Why?
|
Pyrazoles | 1 | 2011 | 74 | 0.090 |
Why?
|
Immunoglobulin G | 2 | 2022 | 451 | 0.090 |
Why?
|
Cysteine-Rich Protein 61 | 1 | 2009 | 4 | 0.090 |
Why?
|
Carcinogenesis | 2 | 2022 | 116 | 0.090 |
Why?
|
Time Factors | 1 | 2017 | 3567 | 0.080 |
Why?
|
Cyclooxygenase 2 | 1 | 2009 | 77 | 0.080 |
Why?
|
Insulin | 1 | 2013 | 687 | 0.080 |
Why?
|
Homeodomain Proteins | 1 | 2011 | 254 | 0.080 |
Why?
|
Neovascularization, Pathologic | 1 | 2009 | 138 | 0.080 |
Why?
|
Insulin-Like Growth Factor Binding Protein 3 | 1 | 2008 | 11 | 0.080 |
Why?
|
Repressor Proteins | 1 | 2011 | 336 | 0.080 |
Why?
|
In Situ Nick-End Labeling | 1 | 2008 | 43 | 0.080 |
Why?
|
Wound Healing | 1 | 2009 | 177 | 0.080 |
Why?
|
Transforming Growth Factor beta1 | 1 | 2008 | 53 | 0.080 |
Why?
|
NF-kappa B | 3 | 2018 | 461 | 0.080 |
Why?
|
Rats | 2 | 2022 | 1907 | 0.080 |
Why?
|
Diarrhea | 2 | 2020 | 73 | 0.080 |
Why?
|
Random Allocation | 1 | 2008 | 198 | 0.070 |
Why?
|
Tumor Microenvironment | 2 | 2020 | 141 | 0.070 |
Why?
|
RNA, Messenger | 1 | 2013 | 1470 | 0.070 |
Why?
|
Reference Values | 1 | 2008 | 323 | 0.070 |
Why?
|
Genome, Human | 1 | 2009 | 219 | 0.070 |
Why?
|
Caspases | 1 | 2008 | 164 | 0.070 |
Why?
|
Disease Susceptibility | 2 | 2021 | 158 | 0.070 |
Why?
|
Risk Factors | 4 | 2020 | 4999 | 0.070 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 1 | 2008 | 525 | 0.070 |
Why?
|
Cell Survival | 2 | 2018 | 553 | 0.070 |
Why?
|
Promoter Regions, Genetic | 2 | 2020 | 659 | 0.070 |
Why?
|
Cyclin D1 | 2 | 2017 | 21 | 0.070 |
Why?
|
Sensitivity and Specificity | 1 | 2008 | 1093 | 0.060 |
Why?
|
Reproducibility of Results | 1 | 2009 | 1549 | 0.060 |
Why?
|
Risk | 2 | 2016 | 371 | 0.060 |
Why?
|
Treatment Outcome | 1 | 2015 | 5142 | 0.060 |
Why?
|
Aged, 80 and over | 3 | 2021 | 5067 | 0.060 |
Why?
|
Interleukin-13 | 1 | 2024 | 35 | 0.060 |
Why?
|
Transcription, Genetic | 1 | 2008 | 847 | 0.060 |
Why?
|
Receptors, CCR7 | 1 | 2022 | 6 | 0.050 |
Why?
|
Spleen | 1 | 2024 | 485 | 0.050 |
Why?
|
Sodium | 1 | 2022 | 60 | 0.050 |
Why?
|
Case-Control Studies | 2 | 2016 | 1061 | 0.050 |
Why?
|
Rodentia | 1 | 2022 | 19 | 0.050 |
Why?
|
Immunoglobulin M | 1 | 2022 | 112 | 0.050 |
Why?
|
Half-Life | 2 | 2012 | 70 | 0.050 |
Why?
|
Breast Density | 1 | 2022 | 16 | 0.050 |
Why?
|
9,10-Dimethyl-1,2-benzanthracene | 1 | 2022 | 8 | 0.050 |
Why?
|
Potassium | 1 | 2022 | 109 | 0.050 |
Why?
|
Caprylates | 1 | 2022 | 12 | 0.050 |
Why?
|
Fluorocarbons | 1 | 2022 | 32 | 0.050 |
Why?
|
Spike Glycoprotein, Coronavirus | 1 | 2022 | 97 | 0.050 |
Why?
|
Hormones | 1 | 2022 | 57 | 0.050 |
Why?
|
Ethiopia | 1 | 2021 | 5 | 0.050 |
Why?
|
Phthalic Acids | 1 | 2022 | 41 | 0.050 |
Why?
|
Environment | 1 | 2022 | 125 | 0.050 |
Why?
|
Recombinational DNA Repair | 1 | 2021 | 20 | 0.050 |
Why?
|
Genetic Linkage | 1 | 2021 | 101 | 0.050 |
Why?
|
B-Lymphocytes | 1 | 2024 | 548 | 0.050 |
Why?
|
Maternal Exposure | 1 | 2021 | 40 | 0.050 |
Why?
|
Bacitracin | 1 | 2020 | 5 | 0.050 |
Why?
|
Rutin | 1 | 2020 | 5 | 0.050 |
Why?
|
Genetic Loci | 1 | 2021 | 106 | 0.050 |
Why?
|
Cell Transformation, Neoplastic | 1 | 2022 | 192 | 0.040 |
Why?
|
Neoplasm Metastasis | 1 | 2021 | 196 | 0.040 |
Why?
|
Hepatocyte Nuclear Factor 3-alpha | 1 | 2020 | 5 | 0.040 |
Why?
|
Rats, Sprague-Dawley | 1 | 2022 | 569 | 0.040 |
Why?
|
GATA3 Transcription Factor | 1 | 2020 | 15 | 0.040 |
Why?
|
CD4-Positive T-Lymphocytes | 1 | 2024 | 609 | 0.040 |
Why?
|
Chromosome Mapping | 1 | 2021 | 294 | 0.040 |
Why?
|
Folic Acid | 1 | 2020 | 58 | 0.040 |
Why?
|
Toxicity Tests | 1 | 2020 | 16 | 0.040 |
Why?
|
Antibodies, Viral | 1 | 2022 | 305 | 0.040 |
Why?
|
Vaccination | 1 | 2022 | 335 | 0.040 |
Why?
|
Hyperplasia | 1 | 2019 | 85 | 0.040 |
Why?
|
Polymorphism, Single Nucleotide | 1 | 2021 | 462 | 0.040 |
Why?
|
Hydroxamic Acids | 1 | 2018 | 27 | 0.040 |
Why?
|
Histone Deacetylase Inhibitors | 1 | 2018 | 31 | 0.040 |
Why?
|
Acetylation | 1 | 2018 | 111 | 0.040 |
Why?
|
Cytotoxins | 1 | 2018 | 12 | 0.040 |
Why?
|
N-Myc Proto-Oncogene Protein | 1 | 2018 | 22 | 0.040 |
Why?
|
Mastectomy | 1 | 2018 | 52 | 0.040 |
Why?
|
Gene Regulatory Networks | 1 | 2019 | 139 | 0.040 |
Why?
|
Chromatography, High Pressure Liquid | 1 | 2018 | 198 | 0.040 |
Why?
|
Tandem Mass Spectrometry | 1 | 2018 | 135 | 0.040 |
Why?
|
Bone Marrow Cells | 1 | 2018 | 231 | 0.040 |
Why?
|
Infant, Newborn | 1 | 2022 | 1311 | 0.040 |
Why?
|
Kaplan-Meier Estimate | 1 | 2018 | 387 | 0.040 |
Why?
|
Antibodies, Blocking | 1 | 2017 | 41 | 0.040 |
Why?
|
Epithelium | 2 | 2008 | 97 | 0.030 |
Why?
|
Receptors, IgE | 1 | 2016 | 7 | 0.030 |
Why?
|
Body Mass Index | 1 | 2020 | 891 | 0.030 |
Why?
|
Maximum Tolerated Dose | 1 | 2016 | 42 | 0.030 |
Why?
|
Child, Preschool | 1 | 2021 | 1838 | 0.030 |
Why?
|
Adoptive Transfer | 1 | 2016 | 145 | 0.030 |
Why?
|
Adipose Tissue | 1 | 2018 | 283 | 0.030 |
Why?
|
Genetic Variation | 1 | 2018 | 367 | 0.030 |
Why?
|
Cohort Studies | 1 | 2022 | 2437 | 0.030 |
Why?
|
Interleukin-6 | 1 | 2017 | 309 | 0.030 |
Why?
|
Interleukin-1beta | 1 | 2017 | 265 | 0.030 |
Why?
|
Mice, SCID | 1 | 2016 | 506 | 0.030 |
Why?
|
Cyclin-Dependent Kinase 2 | 1 | 2014 | 18 | 0.030 |
Why?
|
Mice, Inbred NOD | 1 | 2016 | 515 | 0.030 |
Why?
|
Neoplasm Grading | 1 | 2014 | 74 | 0.030 |
Why?
|
Serine | 1 | 2014 | 83 | 0.030 |
Why?
|
Protein Isoforms | 1 | 2015 | 195 | 0.030 |
Why?
|
Genetic Predisposition to Disease | 1 | 2018 | 677 | 0.030 |
Why?
|
Biomarkers | 1 | 2019 | 1205 | 0.030 |
Why?
|
Cluster Analysis | 1 | 2014 | 250 | 0.030 |
Why?
|
1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine | 1 | 2013 | 4 | 0.030 |
Why?
|
Matrix Metalloproteinase 1 | 1 | 2013 | 8 | 0.030 |
Why?
|
Lymphocyte Activation | 1 | 2016 | 740 | 0.030 |
Why?
|
Intestinal Mucosa | 1 | 2015 | 221 | 0.030 |
Why?
|
Up-Regulation | 1 | 2014 | 363 | 0.030 |
Why?
|
Carcinogens, Environmental | 1 | 2012 | 6 | 0.030 |
Why?
|
Transfection | 1 | 2014 | 673 | 0.030 |
Why?
|
Micrococcus | 1 | 2012 | 3 | 0.030 |
Why?
|
Esters | 1 | 2012 | 19 | 0.030 |
Why?
|
Cell Cycle | 1 | 2014 | 379 | 0.030 |
Why?
|
Enzyme Stability | 1 | 2012 | 46 | 0.030 |
Why?
|
Polymerization | 1 | 2012 | 35 | 0.030 |
Why?
|
Molecular Weight | 1 | 2012 | 187 | 0.020 |
Why?
|
Odds Ratio | 1 | 2014 | 772 | 0.020 |
Why?
|
Area Under Curve | 1 | 2012 | 128 | 0.020 |
Why?
|
Child | 1 | 2021 | 4300 | 0.020 |
Why?
|
Magnetic Resonance Spectroscopy | 1 | 2012 | 292 | 0.020 |
Why?
|
Gamma Rays | 1 | 2011 | 31 | 0.020 |
Why?
|
RNA Interference | 1 | 2014 | 591 | 0.020 |
Why?
|
Microscopy, Fluorescence | 1 | 2012 | 397 | 0.020 |
Why?
|
Particle Size | 1 | 2012 | 398 | 0.020 |
Why?
|
Age Factors | 1 | 2014 | 1518 | 0.020 |
Why?
|
Cross-Sectional Studies | 1 | 2016 | 2464 | 0.020 |
Why?
|
Early Growth Response Protein 1 | 1 | 2008 | 15 | 0.020 |
Why?
|
14-3-3 Proteins | 1 | 2008 | 19 | 0.020 |
Why?
|
Base Sequence | 1 | 2011 | 1312 | 0.020 |
Why?
|
Cell Line, Transformed | 1 | 2008 | 97 | 0.020 |
Why?
|
Ovariectomy | 1 | 2008 | 97 | 0.020 |
Why?
|
Mice, Mutant Strains | 1 | 2008 | 304 | 0.020 |
Why?
|
Molecular Sequence Data | 1 | 2011 | 1977 | 0.020 |
Why?
|
Oligonucleotide Array Sequence Analysis | 1 | 2008 | 291 | 0.020 |
Why?
|
Surveys and Questionnaires | 1 | 2015 | 2589 | 0.020 |
Why?
|
Blotting, Northern | 1 | 2005 | 148 | 0.020 |
Why?
|
Male | 1 | 2024 | 27512 | 0.010 |
Why?
|
Neoplasms | 1 | 2011 | 1234 | 0.010 |
Why?
|